The effect of L-arginine supplementation in patients with congestive heart failure
Phase 3
- Conditions
- congestive heart failure.Systolic (congestive) heart failureI50.2
- Registration Number
- IRCT20170202032367N4
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Age 35-60 years
Diagnosis of ischemic heart failure
Ejection fraction less than 40% (based on echocardiography test)
Cardiac functional level of 2 or 3 based on the classification of the New York heart association
Exclusion Criteria
Kidney, liver or inflammatory bowel diseases, malignancies, thyroid disorders
Pregnancy and lactation
Taking any dietary supplement including L-arginine within the past 2 months prior to the initiation of the study
History of angina pectoris, myocardial infarction or stroke, untreated arrhythmias
Taking medications including glucocorticoids, antiarrhythmic or chemotherapy agents, NSAIDs, diltiazem, verapamil, thiazolidinedione
Unable to perform 6 minute walking test
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method